ангиотензин 调节大脑中血清素的释放和合成
Science (New York, N.Y.)
|December 8, 1978
概括
ангиотензин II 通过通过基酶激活增加其释放和合成来影响血清激素水平. 效果因剂量而异,在高剂量时显示刺激,在低剂量时显示抑制,揭示了复杂的血清系统调节.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 血清素是一种关键的神经递质,参与各种生理过程.
- ангиотензин II 是一种已知对心血管和神经系统有影响的激素.
研究的目的:
- 研究 ангиотензин II 对神经元终端中血清释放和合成的影响.
- 阐明托芬氧化酶在由 ангиотензин II 中介的血清素产生中的作用.
- 描述 ангиотензин II 对血清素系统的剂量依赖性影响.
主要方法:
- 从神经元终端释放的血清的测量.
- 测定托氧化酶活性.
- 施用不同剂量的 ангиотензинII及其代谢产物.
主要成果:
- ангиотензин II 刺激了血清的释放,并通过托氧化酶激活加速了它的合成.
- 观察到一种双相剂量依赖的效果:高剂量刺激,低剂量抑制.
- 高剂量刺激与 ангиотензинII转化为 ангиотензинIII有关,而低剂量抑制可能涉及其他代谢物.
结论:
- ангиотензин II 在氨酸系统中起着调节作用.
- 血清系统表现出由 ангиотензинII及其代谢产物进行微妙的,剂量依赖的调节.
- 这些发现有助于理解氨酸 - ангиотензин 系统和血清蛋白质神经递质之间的相互作用.
更多相关视频
相关概念视频
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...